Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease
Related Experiment Videos
Brynjar Vidarsson1, Deane F Mosher, M Shahriar Salamat
1Department of Hematology and Pathology, Landspitali University Hospital, Hringbraut, 101 Reykjavik, Iceland.
Abstract:
Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.
Related Concept Videos
Cryptococcal Meningitis
Encephalitis ll: Pathophysiology
Hepatic Encephalopathy
Encephalitis l: Introduction
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Cerebral Edema ll: Pathophysiology